Edap Tms S.A. (NASDAQ:EDAP – Get Free Report) was the recipient of a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 58,380 shares, a decline of 34.8% from the February 12th total of 89,522 shares. Based on an average daily volume of 51,440 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.2% of the company’s stock are short sold. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 51,440 shares, the days-to-cover ratio is currently 1.1 days.
Analyst Ratings Changes
Several research firms recently commented on EDAP. Wall Street Zen upgraded Edap Tms to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Edap Tms in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.50.
Check Out Our Latest Report on EDAP
Edap Tms Stock Performance
Institutional Investors Weigh In On Edap Tms
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Financial Planning Navigators CORP purchased a new position in shares of Edap Tms in the fourth quarter worth approximately $33,000. Kovack Advisors Inc. purchased a new stake in Edap Tms during the fourth quarter valued at approximately $53,000. Leonteq Securities AG bought a new position in Edap Tms in the fourth quarter worth approximately $313,000. Flax Pond Capital LLC bought a new position in Edap Tms in the fourth quarter worth approximately $2,623,000. Finally, Rock Springs Capital Management LP boosted its stake in shares of Edap Tms by 1.3% during the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider’s stock worth $4,233,000 after acquiring an additional 16,500 shares during the last quarter. Hedge funds and other institutional investors own 62.74% of the company’s stock.
Edap Tms Company Profile
Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.
Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.
Recommended Stories
- Five stocks we like better than Edap Tms
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- 1,500 Banks Just Handed the Fed Your Bank Account
- Trump Planning to Use Public Law 63-43: Prepare Now
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.
